Kopran — 360° view

Kopran, a company in the Pharmaceuticals industry, reported revenue of ₹211 crore and net profit of ₹4.39 crore for the September 2026 quarter.

Kopran (NSE: KOPRAN) closed at ₹263.16 on 20 Nov 2026, up 96.4% over the past year. Its market capitalisation is ₹1,272 crore and it trades at 32.4 times earnings.

Share price
₹263.16 (20 Nov 2026)
Market cap
₹1,272 Cr (20 Nov 2026)
P/E
32.36 (20 Nov 2026)
Revenue
₹211 Cr (September 2026 quarter)
Net profit
₹4 Cr (September 2026 quarter)
ROCE
6.65% (FY26)
ROE
4.91% (FY26)
Book value
₹109 (FY26)
Dividend yield
1.14% (last 12 months to 20 Nov 2026)
52-week high / low
₹295.83 / ₹107.00 (20 Nov 2026)
1-year return
96.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: KOPRAN

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.